Today: 21 May 2026
IBM stock slips below $300 as Wall Street braces for jobs data and Big Blue earnings
5 January 2026
2 mins read

IBM stock slips below $300 as Wall Street braces for jobs data and Big Blue earnings

New York, Jan 4, 2026, 19:19 ET — Market closed

  • IBM shares closed down 1.6% on Friday at $291.50.
  • Traders head into Monday watching U.S. jobs and inflation data for interest-rate signals.
  • IBM’s fourth-quarter earnings announcement is set for Jan. 28 (preliminary date).

International Business Machines Corp (IBM.N) shares closed down 1.6% at $291.50 on Friday, slipping under the $300 mark after an early drop took the stock as low as $289.00.

The move matters now because the first full week of 2026 brings a cluster of U.S. data that can reset rate expectations, which often steers demand for technology and other long-duration equities. “The market is looking for direction,” Matthew Maley, chief market strategist at Miller Tabak, said. Reuters

Next up are the January 9 U.S. employment report and the January 13 consumer price index release, followed later in the month by the Federal Reserve’s January 27-28 policy meeting.

IBM also has a company-specific catalyst on the calendar: it has set January 28 as a preliminary date for its fourth-quarter earnings announcement. Investors typically focus on software growth, consulting demand and free cash flow in IBM’s results, along with any updates on deal activity.

In the broader market on Friday, the Dow and S&P 500 posted small gains while the Nasdaq ended slightly lower, as U.S. Treasury yields pushed higher. The 10-year Treasury yield — a benchmark interest rate for everything from mortgages to corporate borrowing — rose to about 4.19%.

IBM’s slide mirrored weakness in parts of the IT services and consulting space. Accenture fell 3.1% on Friday and DXC Technology dropped 3.9%, while IBM outperformed some large-cap tech peers in that group’s data snapshot.

A pair of insider filings also crossed investors’ screens. Form 4 disclosures — SEC filings that insiders use to report changes in their holdings — showed directors Michael Miebach and Peter R. Voser deferred fees into “Promised Fee Shares,” stock units that pay out later under IBM’s director compensation plan. SEC

Technically, IBM enters the new week about 10% below its 52-week high of $324.90, with the $289-$290 area flagged by Friday’s session low and $300 a nearby round-number level traders tend to watch. The stock’s 52-week range is $214.50 to $324.90.

In the background, IBM has been leaning on software and hybrid-cloud positioning to keep growth steady as enterprise spending shifts toward data and AI projects. In December, IBM agreed to buy Confluent for about $11 billion, a move aimed at bolstering its cloud push.

But the setup cuts both ways. If the week’s data run hotter and pushes yields higher, the pressure on equity valuations can broaden, and IBM’s defensive label does not always insulate it when rates jump. IBM also faces execution risk: investors will look for clean delivery on margins and cash generation as it integrates acquisitions and competes with consulting and cloud rivals.

For IBM shares, the next hard catalyst is January 28. Before that, traders will take their cues from Friday’s jobs report and the January 13 inflation print as they set expectations for the Fed’s late-January meeting.

Stock Market Today

  • Bitmine Immersion Technologies Uplists to NYSE, Holds 5M+ ETH as Ethereum Proxy, Launches MAVAN Staking
    May 21, 2026, 12:11 AM EDT. Bitmine Immersion Technologies (NYSE:BMNR) has become a major Ethereum proxy by accumulating over 5 million ETH, representing more than 4.3% of Ethereum's total supply. The company uplisted to the NYSE and introduced MAVAN, an institutional-grade Ethereum staking platform, shifting its focus beyond mining to include staking services. BMNR stock closed at $19.39, trading below analyst targets and experiencing recent price declines despite longer-term gains. Investors should watch Ethereum price trends, staking yields, and institutional adoption of MAVAN, while noting BMNR remains loss-making and has diluted shareholders.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
CrowdStrike stock fell 3% Friday — what to watch before markets reopen
Previous Story

CrowdStrike stock fell 3% Friday — what to watch before markets reopen

Cisco stock set for Monday spotlight after $2 billion Axonius deal report, ex-dividend drop
Next Story

Cisco stock set for Monday spotlight after $2 billion Axonius deal report, ex-dividend drop

Go toTop